Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.33588/rn.7009.2020155 http://scihub22266oqcxt.onion/10.33588/rn.7009.2020155 32329046!ä!32329046 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 294.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Neurol 2020 ; 70 (9): 329-340 Nephropedia Template TP {{tp|p=32329046|t=2020. Documento EMCAM (Esclerosis Multiple Comunidad Autonoma de Madrid) para el manejo de pacientes con esclerosis multiple durante la pandemia de SARS-CoV-2 |pdf=|usr=}}{{32329046}} gab.com Text Documento EMCAM (Esclerosis Multiple Comunidad Autonoma de Madrid) para el manejo de pacientes con esclerosis multiple durante la pandemia de SARS-CoV-2 JO: Rev Neurol http://www.kidney.de/pget.php?&tw=1&pmid=32329046 #FOAvip INTRODUCTION: The current SARS-CoV-2 pandemic is forcing neurologists to carry out a series of adaptations in the management of multiple sclerosis. Neurologists must weigh up the need to start or continue disease-modifying treatments against the risk of infection, the risk of complications from the infection, and the risk of multiple sclerosis activity. Since this is an unprecedented situation, most decisions are being made on the basis of a theoretical approach and the criteria of each neurologist. AIMS: The aim of this study is conduct a literature search to collect available evidence on the relationship between disease-modifying therapies in multiple sclerosis and SARS-CoV-2 infection. This evidence, together with the experience of the authors in the management of patients with multiple sclerosis during the pandemic, will make it possible to offer some proposals for the treatment and follow-up of patients in this epidemiological context. DEVELOPMENT: After the literature search and our experience in the management of patients, a number of proposals for treatment are established for each drug, which must necessarily be individualised for each patient, since, in these exceptional circumstances, their peculiarities can affect the prognosis. CONCLUSIONS: The neurologist should be aware of current evidence to assess the risk-benefit of starting, maintaining and stopping disease-modifying therapies in multiple sclerosis during the pandemic. Twit Text FOAVip Documento EMCAM (Esclerosis Multiple Comunidad Autonoma de Madrid) para el manejo de pacientes con esclerosis multiple durante la pandemia de SARS-CoV-2 ????Rev Neurol http://www.kidney.de/pget.php?&tw=1&pmid=32329046 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32329046 #FOAvip English Wikipedia <ref>{{Cite pmid|32329046}}</ref> Documento EMCAM (Esclerosis Multiple Comunidad Autonoma de Madrid) para el manejo de pacientes con esclerosis multiple durante la pandemia de SARS-CoV-2 #MMPMID32329046 Costa-Frossard L; Moreno-Torres I; Meca-Lallana V; Garcia-Dominguez JM; En Representacion Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autonoma de Madrid ERDGEEDCAM Rev Neurol 2020[May]; 70 (9): 329-340 PMID32329046show ga INTRODUCTION: The current SARS-CoV-2 pandemic is forcing neurologists to carry out a series of adaptations in the management of multiple sclerosis. Neurologists must weigh up the need to start or continue disease-modifying treatments against the risk of infection, the risk of complications from the infection, and the risk of multiple sclerosis activity. Since this is an unprecedented situation, most decisions are being made on the basis of a theoretical approach and the criteria of each neurologist. AIMS: The aim of this study is conduct a literature search to collect available evidence on the relationship between disease-modifying therapies in multiple sclerosis and SARS-CoV-2 infection. This evidence, together with the experience of the authors in the management of patients with multiple sclerosis during the pandemic, will make it possible to offer some proposals for the treatment and follow-up of patients in this epidemiological context. DEVELOPMENT: After the literature search and our experience in the management of patients, a number of proposals for treatment are established for each drug, which must necessarily be individualised for each patient, since, in these exceptional circumstances, their peculiarities can affect the prognosis. CONCLUSIONS: The neurologist should be aware of current evidence to assess the risk-benefit of starting, maintaining and stopping disease-modifying therapies in multiple sclerosis during the pandemic. |*Disease Management[MESH] |*Immunosuppressive Agents/adverse effects/therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/epidemiology[MESH] |Decision Making[MESH] |Humans[MESH] |Multiple Sclerosis/complications/*drug therapy[MESH] |Neurologists[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/epidemiology[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Documento EMCAM (Esclerosis Multiple Comunidad Autonoma de Madrid) par(epmc).pdf DeepDyve Pubget Overpricing